Related Experiment Video

Updated: May 13, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Molecular markers of therapeutic resistance in breast cancer

Ling Zhou1, Yanli Luo, Ke Li

  • 1Department of Surgery, Shanghai First People's Branch Hospital, Shanghai Jiaotong University, Shanghai 200081, China.

Human Pathology
|February 26, 2013
PubMed

Insights

New biomarkers, including aldehyde dehydrogenase 1, cleaved caspase 3, and cyclooxygenase 2, show promise for predicting breast cancer treatment resistance and patient survival outcomes.

Area of Science:

  • Oncology
  • Biomarker Research
  • Cancer Therapeutics

Background:

  • Therapeutic resistance to chemotherapy and endocrine therapy presents a significant challenge in breast cancer management.
  • The identification of specific biomarkers to predict treatment resistance remains an unmet clinical need.

Purpose of the Study:

  • To investigate the predictive value of aldehyde dehydrogenase 1 (ALDH1), cleaved caspase 3 (CC3), cyclooxygenase 2 (COX-2), phosphorylated Akt (p-Akt), Ki-67, and H2AX protein expression for therapeutic resistance in breast cancer patients.
  • To assess the correlation of these protein expressions with relapse rates and survival outcomes across different treatment modalities.

Main Methods:

  • Immunohistochemical staining was employed to quantify the expression levels of target proteins in 113 breast cancer tissue samples.
  • Patients received chemotherapy, endocrine therapy, or a combination of both.
  • Statistical analyses were performed to evaluate the association between protein expression and clinical outcomes, including relapse and survival.

Main Results:

  • ALDH1, CC3, and COX-2 expression significantly correlated with increased relapse rates and reduced survival in triple-negative breast cancer patients undergoing chemotherapy.
  • COX-2 was identified as an independent predictor of poor prognosis.
  • ALDH1 expression was associated with shorter survival in patients receiving combined therapy, but not with relapse.

Conclusions:

  • ALDH1, CC3, and COX-2 show potential as valuable biomarkers for predicting therapeutic resistance in breast cancer.
  • These findings may aid in personalizing treatment strategies and improving patient outcomes by identifying individuals at higher risk of resistance.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...